Prof Helena Earl speaks to ecancer about the reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer.
Initially, she explains that this systematic review identified five NI RCTs, and trial groups agreed a meta-analysis collaboration.
Prof Earl then discusses the methodology and results of this study. She says that this study proved that six months trastuzumab is non-inferior to 12months, although nine weeks is not.
She concludes by discussing the impact these results could have on the future of treating breast cancer.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.